THE PNOC DIFFERENCE
Our highly ambitious, high reward research will change the course of pediatric brain cancer and save and improve children’s lives.
Through ground-breaking collaboration across 18 institutions and 100+ clinicians and researchers, we bring treatments to patients as quickly as possible and well below the 18-month average.
Traditional brain cancer protocols do not mandate tissue samples, and apply blanket treatments which can lead to ineffective treatments and serious adverse side effects. PNOC trials are based on precision medicine and immunotherapy, because we understand that each tumor is as unique as each child.
BREAKTHROUGHS FOR ALL
Many of our trials, if successful, will change the landscape for both children and adults. There are currently 16 active clinical trials underway. Example of current trials:
• Using a modified measles virus to target one of pediatric brain cancer’s most aggressive and currently untreatable forms, AT/RT and recurrent medulloblastoma.
• The first ever testing of repeated injections of a nanoparticle embedded with a chemotherapy agent into the brainstem of children using flexible catheters.
PNOC is currently treating 140 children with cutting edge treatments, and aims to offer care to at least 200 children per year by 2019.